Cargando…
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
In the past few years, Bruton’s tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk inhibitors have been launched on the market. In the at...
Autores principales: | Brullo, Chiara, Villa, Carla, Tasso, Bruno, Russo, Eleonora, Spallarossa, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303217/ https://www.ncbi.nlm.nih.gov/pubmed/34299259 http://dx.doi.org/10.3390/ijms22147641 |
Ejemplares similares
-
The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021) -
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021) -
The Development of FAK Inhibitors: A Five-Year Update
por: Spallarossa, Andrea, et al.
Publicado: (2022) -
Nanotechnology for Pediatric Retinoblastoma Therapy
por: Russo, Eleonora, et al.
Publicado: (2022) -
Indole Antitumor Agents in Nanotechnology Formulations: An Overview
por: Russo, Eleonora, et al.
Publicado: (2023)